– USA, MA – Korro Bio, Inc., a biotechnology company developing single-base RNA editing therapies, today announced the appointment of Dr. Ram Aiyar, Ph.D., to its board of directors as its CEO, bringing nearly 20 years of diverse experience across company-building, biotech and pharma to advance Korro’s innovative RNA editing platform to treat previously intractable diseases.
“Ram is a proven leader with a track record of driving growth and advancing programs,” said co-founder and executive chair, Dr. Nessan Bermingham. “His broad business experience across the life sciences complements our existing leadership team. We look forward to working closely with him to pioneer the future of RNA editing for medicines.”
About Dr. Ram Aiyar
Dr. Aiyar has a long history of launching and building biotech startups, previously holding a wide range of roles in finance, strategy, product development, and venture capital. Most recently, he was a co-founder, chief financial officer, and chief business officer at Corvidia Therapeutics, a private Boston-based cardio-renal company. He was instrumental in the company creation and eventually led the transaction resulting in a successful acquisition by Novo Nordisk for $2.1B. Before Corvidia, Dr. Aiyar was an entrepreneur-in-residence at BioHealth Innovation. There he led the creation and the progression of multiple early-stage companies across several therapeutic areas. He started his scientific career in research at Janssen Pharmaceuticals’ immunology group, where he was a member of several compound development teams across all stages of development. Dr. Aiyar has also held leadership roles in corporate development, finance, and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.
“I’m excited and honored to join the exceptional team at Korro,” said Dr. Aiyar. “Our RNA editing platform provides a novel approach to treating diseases by repairing and modulating protein function. I look forward to leading the company with the goal of bringing innovative therapies for patients.”
He received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD.
About Korro Bio, Inc.
Korro is leading the next frontier in RNA therapeutics. Its proprietary platform, OPERA, harnesses the body’s own RNA editing system to make a precise edit to a single-base. Korro’s therapeutic approach utilizes synthetic oligonucleotides to repair disease-causing mutations at the RNA level. This approach can also be used to create therapeutically beneficial versions of proteins to improve patient outcomes. Korro’s programs target a broad portfolio of innovative RNA editing therapies in the liver, eye, and central nervous system. The company was founded in 2018 by Atlas Venture and is funded by Atlas Venture, New Enterprise Associates, Wu Capital, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, and Alexandria Venture Investments.
For more information: https://www.korrobio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
